GSK to Buy Nuvalent for $10.6 Billion in Oncology Push
RSS SUMMARY · AGGREGATED FROM TWSJ
The acquisition is set to give GSK ownership of three drug candidates for lung cancer, two of which are under FDA review for approval this year.
The acquisition is set to give GSK ownership of three drug candidates for lung cancer, two of which are under FDA review for approval this year.
The acquisition is set to give GSK ownership of three drug candidates for lung cancer, two of which are under FDA review for approval this year.
Continue Reading
The full story continues on The Wall Street Journal.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.
The Source
TWSJ
Business
U.S. Small-Business Confidence Ticked Down in May
TWSJ·54m ago·3 min read
World News
China’s Xi Projects Strength. His Constant Purges Reveal Insecurity.
TWSJ·13m ago·3 min read
Business
A Rush to Stockpile Oil Will Keep Prices Higher for Longer
TWSJ·1h ago·3 min read
Business
Why Does It Take Years to Get a Patriot Missile From Factory to Front Line?
TWSJ·1h ago·3 min read
Related
On this beat
Business
U.S. Small-Business Confidence Ticked Down in May
TWSJ·54m ago·3 min read
Business
Pet Owners Completely Overlook This 1 Disastrous Scenario. A New Tech Startup Thinks It Has the Solution
INC·1h ago·3 min read
Business
Walmart is selling a $300 all-weather storage shed for only $170 in time for summer
THE STREET·38m ago·3 min read
Business
Oracle faces vital AI reality check in upcoming earnings
THE STREET·35m ago·3 min read